LC 224/25 and Its Impacts on the Pharmaceutical Sector: Price Increases and the Principle of Essentiality

LC 224/25 reduces tax incentives for medicines by limiting presumed PIS/Cofins credits, increasing the sector’s effective tax burden. This may lead to higher drug prices, especially in a market already above inflation. The change also raises concerns about unequal treatment of essential goods, particularly medicines versus food.